Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease

Abstract Background Non-alcoholic steatohepatitis (NASH) progression is strongly associated with deteriorating hepatic function, primarily driven by free cholesterol (FC) accumulation-induced lipotoxicity. Emerging evidence highlights the regulatory role of mammalian Ste20-like kinase 1 (MST1) in mo...

Full description

Saved in:
Bibliographic Details
Main Authors: Lijuan Wang, Chenglei Zhang, Jie Ma, Jiarui Li, Yuanyuan Wu, Yanru Ren, Jianning Li, Yan Li, Yi Yang
Format: Article
Language:English
Published: BMC 2025-04-01
Series:European Journal of Medical Research
Subjects:
Online Access:https://doi.org/10.1186/s40001-025-02557-9
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850146359498244096
author Lijuan Wang
Chenglei Zhang
Jie Ma
Jiarui Li
Yuanyuan Wu
Yanru Ren
Jianning Li
Yan Li
Yi Yang
author_facet Lijuan Wang
Chenglei Zhang
Jie Ma
Jiarui Li
Yuanyuan Wu
Yanru Ren
Jianning Li
Yan Li
Yi Yang
author_sort Lijuan Wang
collection DOAJ
description Abstract Background Non-alcoholic steatohepatitis (NASH) progression is strongly associated with deteriorating hepatic function, primarily driven by free cholesterol (FC) accumulation-induced lipotoxicity. Emerging evidence highlights the regulatory role of mammalian Ste20-like kinase 1 (MST1) in modulating intrahepatic lipid homeostasis, suggesting its therapeutic potential for non-alcoholic fatty liver disease (NAFLD) management. This investigation seeks to elucidate the pathophysiological mechanisms through which MST1 modulates NASH progression. Methods The experimental design employed two murine genetic models—wild-type (WT) controls and MST1-knockout (MST1-KO) specimens—subjected to a nutritionally modified Western diet (WD) enriched with saturated fats, simple carbohydrates, and dietary cholesterol to induce non-alcoholic steatohepatitis (NASH) pathogenesis. Lentiviral transduction techniques facilitated targeted MST1 overexpression in WT animals maintained on this dietary regimen. Parallel in vitro investigations utilized HepG2 hepatocyte cultures exposed to free fatty acid (FFA) cocktails comprising palmitic and oleic acids, coupled with CRISPR-mediated MST1 suppression and complementary gain-of-function manipulations to delineate molecular mechanisms. Results NASH triggers hepatic sterol biosynthesis activation, resulting in pathological FC overload concurrent with MST1 transcriptional suppression. Genetic ablation of MST1 amplifies intrahepatic FC retention and potentiates histopathological inflammation, while MST1 reconstitution mitigates steatotic FC deposition and attenuates inflammatory cascades. Mechanistic profiling revealed MST1-mediated AMPKα phosphorylation at Thr172, which suppresses cholesterogenic enzyme expression via sterol regulatory element-binding transcription factor 2 (SREBP2) axis modulation. This phosphorylation cascade demonstrates dose-dependent inhibition of HMGCR activity, resolving FC-induced hepatotoxicity. Crucially, MST1 orchestrates AMPK/SREBP2 crosstalk to maintain sterol homeostasis, with knockout models exhibiting 67% elevated SREBP2 nuclear translocation compared to controls. Conclusions The regulatory axis involving MST1-mediated AMPK phosphorylation emerges as a promising therapeutic modality for modulating hepatic sterol metabolism. It demonstrates significant potential in arresting the progression of inflammatory cascades and extracellular matrix remodeling characteristic of NASH pathogenesis. Mechanistic studies confirm that this phosphorylation cascade effectively suppresses de novo lipogenesis while enhancing cholesterol efflux capacity, thereby establishing a dual-target strategy against both metabolic dysfunction and fibrotic transformation in preclinical models.
format Article
id doaj-art-5c7e3bbd45594807814a9dcd48e19654
institution OA Journals
issn 2047-783X
language English
publishDate 2025-04-01
publisher BMC
record_format Article
series European Journal of Medical Research
spelling doaj-art-5c7e3bbd45594807814a9dcd48e196542025-08-20T02:27:51ZengBMCEuropean Journal of Medical Research2047-783X2025-04-0130112010.1186/s40001-025-02557-9Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver diseaseLijuan Wang0Chenglei Zhang1Jie Ma2Jiarui Li3Yuanyuan Wu4Yanru Ren5Jianning Li6Yan Li7Yi Yang8School of Basic Medical Sciences, Ningxia Medical UniversityMedical Laboratory, General Hospital of Ningxia Medical UniversitySchool of Basic Medical Sciences, Ningxia Medical UniversitySchool of Basic Medical Sciences, Ningxia Medical UniversityDepartment of Oncology, Cancer Hospital, General Hospital of Ningxia Medical UniversityDepartment of Endocrinology, General Hospital of Ningxia Medical UniversitySchool of Basic Medical Sciences, Ningxia Medical UniversitySchool of Basic Medical Sciences, Ningxia Medical UniversitySchool of Basic Medical Sciences, Ningxia Medical UniversityAbstract Background Non-alcoholic steatohepatitis (NASH) progression is strongly associated with deteriorating hepatic function, primarily driven by free cholesterol (FC) accumulation-induced lipotoxicity. Emerging evidence highlights the regulatory role of mammalian Ste20-like kinase 1 (MST1) in modulating intrahepatic lipid homeostasis, suggesting its therapeutic potential for non-alcoholic fatty liver disease (NAFLD) management. This investigation seeks to elucidate the pathophysiological mechanisms through which MST1 modulates NASH progression. Methods The experimental design employed two murine genetic models—wild-type (WT) controls and MST1-knockout (MST1-KO) specimens—subjected to a nutritionally modified Western diet (WD) enriched with saturated fats, simple carbohydrates, and dietary cholesterol to induce non-alcoholic steatohepatitis (NASH) pathogenesis. Lentiviral transduction techniques facilitated targeted MST1 overexpression in WT animals maintained on this dietary regimen. Parallel in vitro investigations utilized HepG2 hepatocyte cultures exposed to free fatty acid (FFA) cocktails comprising palmitic and oleic acids, coupled with CRISPR-mediated MST1 suppression and complementary gain-of-function manipulations to delineate molecular mechanisms. Results NASH triggers hepatic sterol biosynthesis activation, resulting in pathological FC overload concurrent with MST1 transcriptional suppression. Genetic ablation of MST1 amplifies intrahepatic FC retention and potentiates histopathological inflammation, while MST1 reconstitution mitigates steatotic FC deposition and attenuates inflammatory cascades. Mechanistic profiling revealed MST1-mediated AMPKα phosphorylation at Thr172, which suppresses cholesterogenic enzyme expression via sterol regulatory element-binding transcription factor 2 (SREBP2) axis modulation. This phosphorylation cascade demonstrates dose-dependent inhibition of HMGCR activity, resolving FC-induced hepatotoxicity. Crucially, MST1 orchestrates AMPK/SREBP2 crosstalk to maintain sterol homeostasis, with knockout models exhibiting 67% elevated SREBP2 nuclear translocation compared to controls. Conclusions The regulatory axis involving MST1-mediated AMPK phosphorylation emerges as a promising therapeutic modality for modulating hepatic sterol metabolism. It demonstrates significant potential in arresting the progression of inflammatory cascades and extracellular matrix remodeling characteristic of NASH pathogenesis. Mechanistic studies confirm that this phosphorylation cascade effectively suppresses de novo lipogenesis while enhancing cholesterol efflux capacity, thereby establishing a dual-target strategy against both metabolic dysfunction and fibrotic transformation in preclinical models.https://doi.org/10.1186/s40001-025-02557-9Mammalian sterile 20-like kinase 1AMP-activated protein kinaseCholesterol synthesisHepatic free cholesterolNon-alcoholic steatohepatitis
spellingShingle Lijuan Wang
Chenglei Zhang
Jie Ma
Jiarui Li
Yuanyuan Wu
Yanru Ren
Jianning Li
Yan Li
Yi Yang
Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
European Journal of Medical Research
Mammalian sterile 20-like kinase 1
AMP-activated protein kinase
Cholesterol synthesis
Hepatic free cholesterol
Non-alcoholic steatohepatitis
title Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
title_full Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
title_fullStr Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
title_full_unstemmed Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
title_short Mammalian Ste20-like kinase 1 regulates AMPK to mitigate the progression of non-alcoholic fatty liver disease
title_sort mammalian ste20 like kinase 1 regulates ampk to mitigate the progression of non alcoholic fatty liver disease
topic Mammalian sterile 20-like kinase 1
AMP-activated protein kinase
Cholesterol synthesis
Hepatic free cholesterol
Non-alcoholic steatohepatitis
url https://doi.org/10.1186/s40001-025-02557-9
work_keys_str_mv AT lijuanwang mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT chengleizhang mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT jiema mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT jiaruili mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT yuanyuanwu mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT yanruren mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT jianningli mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT yanli mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease
AT yiyang mammalianste20likekinase1regulatesampktomitigatetheprogressionofnonalcoholicfattyliverdisease